ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the ...

An update from MaxCyte ( (MXCT)) is now available. On March 16, 2026, MaxCyte received notice from Nasdaq that its common stock had closed below $1.00 per share for 30 consecutive trading days, ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks MaxCyte ( (MXCT)) has provided an ...

MaxCyte (NASDAQ:MXCT) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate MaxCyte to report an ...

ROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing solutions to advance ...

Maryland-based MaxCyte focuses on cell-engineering platform technology to serve the biotech industry. In its preliminary report, the cell engineering company lowered its full-year guidance and relayed ...

MaxCyte Inc MXCT shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced customer activity in the sector.

GAITHERSBURG, Md.--(BUSINESS WIRE)--MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at Cambridge Health Institute’s BioProcessing ...

ROCKVILLE, MD—On a brisk, sun-splashed midweek morning in the suburbs of Washington DC, the staff at MaxCyte have double reason to celebrate. Every Wednesday, they are treated to free lunch in the ...

GAITHERSBURG, Md., Sept. 9, 2020 /PRNewswire/ -- MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief ...